(Q38611895)

4 September 2017

title

Immunological landscape and immunotherapy of hepatocellular carcinoma (English)

1 reference

4 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26484443%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Bruno Sangro

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26484443%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Ignacio Melero, MD-PhD

series ordinal

2

object named as

Ignacio Melero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26484443%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

English

0 references

publication date

20 October 2015

1 reference

Nature Reviews Gastroenterology & Hepatology

4 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26484443%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26484443%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26484443%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

681-700

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26484443%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrgastro.2015.173

5 June 2020

exact match

0 references

cites work

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Prognosis of untreated hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Multistep human hepatocarcinogenesis: correlation of imaging with pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

CD40 signaling to the rescue: A CD8 exhaustion perspective in chronic infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A special population of regulatory T cells potentiates muscle repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Effect of NKG2D ligand expression on host immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Adenosine receptors and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Macrophages regulate the angiogenic switch in a mouse model of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Stromal fibroblasts in cancer: a novel tumor-promoting cell type

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Role of the microenvironment in hepatocellular carcinoma development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Regulatory T cells: mechanisms of differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Immune control in hepatocellular carcinoma development and progression: role of stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Amphiregulin: a new growth factor in hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Clinical blockade of PD1 and LAG3--potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

LAG-3, a novel lymphocyte activation gene closely related to CD4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

TGF-beta and kynurenines as the key to infectious tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Creating immune privilege: active local suppression that benefits friends, but protects foes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Galectins as modulators of tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Galectins and their ligands: negative regulators of anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tumor-associated galectin-3 modulates the function of tumor-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

RECIST revisited: a review of validation studies on tumour assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Therapeutic cancer vaccines: current status and moving forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Improved endpoints for cancer immunotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Dendritic cells and cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Harnessing Human Cross-Presenting CLEC9A(+)XCR1(+) Dendritic Cells for Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Improving the efficacy and safety of engineered T cell therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

HLA ligandome tumor antigen discovery for personalized vaccine approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Glypicans: proteoglycans with a surprise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Glypican-3 antibodies: a new therapeutic target for liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Agonist antibodies to TNFR molecules that costimulate T and NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Gene therapy of liver diseases: a 2011 perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Recent advances in oncolytic virus design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

In situ production of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Immunological off-target effects of standard treatments in gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Self-inactivating helper virus for the production of high-capacity adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Biomarkers on melanoma patient T cells associated with ipilimumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

TGF-β-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

NKG2D and its ligands: key to immunotherapy of liver cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Netrin-1 induces epithelial-mesenchymal transition and promotes hepatocellular carcinoma invasiveness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Hypoxia-induced secretion of platelet-derived growth factor-BB by hepatocellular carcinoma cells increases activated hepatic stellate cell proliferation, migration and expression of vascular endothelial growth factor-A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four -Fetoprotein Peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.173

Gene therapy for liver cancer: clinical experience and future prospects

31 March 2020

1 reference

12 December 2020

Expression and function of interleukin-8 in human hepatocellular carcinoma.

1 reference

12 December 2020

Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma

1 reference

12 December 2020

The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine

1 reference

12 December 2020

NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors

1 reference

12 December 2020